NCT06383390

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Name: Clinical Trial NCT06383390
Creator: Eli Lilly and Company
Keywords: Overweight and Obesity, Retatrutide, Phase 3, drug, clinical trial, Argentina,Australia,Austria,Brazil,Canada,Czech,Denmark,France,Germany,Hungary,India,Israel,Mexico,N

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index ≥27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.

Eli Lilly and Company·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Overweight and Obesity
Drug/Device/Intervention: Retatrutide
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Eli Lilly and Company
Location: Birmingham,Daphne,Huntsville,Mobile,Anchorage,Paradise Valley,Phoenix,Phoenix,Tucson,Little Rock,Apple Valley,Beverly Hills,Canoga Park,Covina,Escondido,Fountain Valley,La Jolla,Lynwood,Northridge,Pas, Argentina,Australia,Austria,Brazil,Canada,Czech,Denmark,France,Germany,Hungary,India,Israel,Mexico,N

Timeline & enrollment

Phase: Phase 3
Start date: May 01, 2024
End date: Feb 01, 2029
Enrollment: 10000 participants

Primary outcome

Time to First Occurrence of Composite Endpoints,Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death

Summary

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease.

ICD-10 classifications

ObesityOther obesityObesity due to excess caloriesObesity, unspecifiedObesity and other hyperalimentation

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06383390
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06383390 through Pure Global AI's free database. This Phase 3 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Overweight and Obesity. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.